Patents Examined by Ilia I Ouspenski
-
Patent number: 11649289Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.Type: GrantFiled: August 3, 2017Date of Patent: May 16, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
-
Patent number: 11648270Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: GrantFiled: March 8, 2019Date of Patent: May 16, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
-
Patent number: 11649283Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.Type: GrantFiled: April 14, 2017Date of Patent: May 16, 2023Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
-
Patent number: 11643464Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.Type: GrantFiled: December 27, 2019Date of Patent: May 9, 2023Assignee: Yeda Research and Develpment & Co. LtdInventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
-
Patent number: 11643452Abstract: Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of Fc?RI?. Notably, CAR constructs with an intracellular domain of Fc?RI? had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.Type: GrantFiled: June 7, 2021Date of Patent: May 9, 2023Assignee: ImmunityBio, Inc.Inventors: Laurent H. Boissel, Hans G. Klingemann, Abhijit Dandapat, Himani Chinnapen
-
Patent number: 11639385Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.Type: GrantFiled: December 27, 2019Date of Patent: May 2, 2023Assignee: PD-1 Acquisition Group, LLCInventors: Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
-
Patent number: 11634493Abstract: The present invention provides a tumor immunotherapy target and use thereof, specifically provides use of the LSECtin expressed by infiltrating tumor-associated macrophage and BTN3A3 expressed by tumor solely or in combination as a target in tumor immunotherapy, and further provides a substance capable of inhibiting the activity of LSECtin expressed by infiltrating tumor-associated macrophage, the activity of BTN3A3 expressed by tumor, or the interaction of the LSECtin with BTN3A3, including RNA molecules, fusion protein BTN3A3-Ig, and monoclonal antibody 5E08, which can be used as an active ingredient to prepare a tumor immunotherapy drug, and is suitable for industrial applications.Type: GrantFiled: November 2, 2017Date of Patent: April 25, 2023Assignee: BEIJING PROTEOME RESEARCH CENTERInventors: Li Tang, Fuchu He, Di Liu, Qian Lu
-
Patent number: 11633430Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.Type: GrantFiled: May 23, 2022Date of Patent: April 25, 2023Assignee: CELLULAR BIOMEDICINE GROUP, INC.Inventors: Yihong Yao, Yanfeng Li, Yutian Wei, Shigui Zhu, Xin Yao, Jiaqi Huang
-
Patent number: 11634492Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.Type: GrantFiled: April 13, 2021Date of Patent: April 25, 2023Assignee: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD.Inventors: Ting Xu, Kangping Guo, Dong Yang, Pilin Wang, Yuhao Jin, Xiaoxiao Wang
-
Patent number: 11629189Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Assignee: KYMAB LIMITEDInventors: Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
-
Patent number: 11629178Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: April 18, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11618775Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: April 4, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11613563Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: March 28, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11612426Abstract: Provided herein are new compositions, methods, and devices to treat cancer through a combination of immunologic chemotherapeutic agents and ablation techniques. These compositions can include immune checkpoint inhibitors, cytokines and nucleic acid drugs that aid in eliciting an immune response to treat the tumor. The administration of these compositions in addition to various ablating techniques provides a presentation of the cancer cell antigens to the immune system and the immunologic targeting of the cancer.Type: GrantFiled: January 13, 2017Date of Patent: March 28, 2023Assignee: ImmunSys, Inc.Inventors: Gary Onik, James A. Miessau, DG Bostwick
-
Patent number: 11608368Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: March 21, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11603398Abstract: Provided herein are methods and compositions for the amelioration of inflammatory disorders comprising the intestinal expression of programmed death ligand 1.Type: GrantFiled: November 9, 2017Date of Patent: March 14, 2023Inventors: Shauna Marie Dauphinee, Connor Daniel Alexander McCarthy, Jeremy Dupaul-Chicoine, Eric Hsu, Ghania Chikh, Anthony Cheung
-
Patent number: 11597754Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.Type: GrantFiled: July 2, 2019Date of Patent: March 7, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
-
Patent number: 11572397Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: February 7, 2023Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 11560430Abstract: Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.Type: GrantFiled: August 16, 2019Date of Patent: January 24, 2023Assignee: Tayu Huaxia Biotech Medical Group Co., LTDInventors: Lieping Chen, Liqun Luo
-
Patent number: 11548948Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: GrantFiled: December 19, 2018Date of Patent: January 10, 2023Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev